2018
Outcomes of serial MRI/ultrasound fusion targeted biopsy in men with very low-risk and low-risk prostate cancer managed with active surveillance.
Hsiang W, Ghabili K, Syed J, Nguyen K, Suarez-Sarmiento A, Leapman M, Sprenkle P. Outcomes of serial MRI/ultrasound fusion targeted biopsy in men with very low-risk and low-risk prostate cancer managed with active surveillance. Journal Of Clinical Oncology 2018, 36: 114-114. DOI: 10.1200/jco.2018.36.6_suppl.114.Peer-Reviewed Original ResearchMRI/US fusion biopsyLow-risk prostate cancerNational Comprehensive Cancer NetworkFusion biopsyActive surveillanceSystematic biopsyProstate cancerGleason upgradeMagnetic resonance imagingPSA densitySubsequent biopsyFavorable-risk prostate cancerMRI/ultrasound fusionSerial magnetic resonance imagingProportion of patientsRisk prostate cancerComprehensive Cancer NetworkLow-risk criteriaRisk of reclassificationLogistic regression modelsBiopsy upgradeMedian PSAGleason scoreHigher PSAInstitutional database
2016
Change in a 17-gene genomic prostate score over time in men with low- and intermediate-risk prostate cancer managed with active surveillance.
Leapman M, Cowan J, Nguyen H, Cooperberg M, Carroll P. Change in a 17-gene genomic prostate score over time in men with low- and intermediate-risk prostate cancer managed with active surveillance. Journal Of Clinical Oncology 2016, 34: 124-124. DOI: 10.1200/jco.2016.34.2_suppl.124.Peer-Reviewed Original ResearchGenomic Prostate ScoreAdverse pathological findingsActive surveillanceProstate cancerRadical prostatectomyPathological findingsFavorable-risk prostate cancerIntermediate-risk prostate cancerIntermediate clinical riskNCCN risk classificationSerial prostate biopsyRisk prostate cancerSubsequent clinical outcomesTime of surgeryRT-PCR assaysPT3a diseaseDefinitive therapyIntermediate riskOncologic outcomesClinical outcomesAdverse pathologySerial biopsiesProstate biopsyMedian changeSerial changes